Title:
エリスロポエチンの使用
Document Type and Number:
Japanese Patent JP4727988
Kind Code:
B2
Abstract:
Use of erythropoetin (EPO) and/or its derivatives for stimulating, in endothelial precursor cells (EPC), any of physiological mobilization; proliferation; differentiation to endothelial cells and/or migration, in the direction of an angiogenic or vasculogenic stimulus. Independent claims are also included for the following: (1) use of EPO and/or its derivatives for stimulating formation of endothelial cells (EC) and/or for vasculogenesis; (2) use of EPO to produce a transplantable EC product; (3) use of EPO for treating a tissue or organ transplant; (4) use of EPO for pretreatment of tissue or organ transplants; (5) use of EPO to prepare implantable or transplantable, cell-containing in vitro organ or tissue systems; (6) use of EPO for coating vascular prostheses or heart valves; and (7) pharmaceutical composition containing (a) EPO, its derivatives, analogs, modifications or muteins and (b) at least one of vascular endothelial growth factor, PIGF (not defined), granulocyte-macrophage colony-stimulating factor and/or a hydroxymethyl glutarate-CoA reductase inhibitor. ACTIVITY : Antilipemic; Antidiabetic; Antiinflammatory; Antiarteriosclerosis; Cardiant; Vasotropic; Antianginal; Gynecological; Hypotensive; Nephrotropic. No details of tests for any of these activities are given. MECHANISM OF ACTION : Treatment with EPO increases adhesion of EPC and stimulates formation of endothelial tissue and blood vessels.
Inventors:
Burman, Ferdinand, Herman
Harrah, Harman
Harrah, Harman
Application Number:
JP2004525322A
Publication Date:
July 20, 2011
Filing Date:
July 25, 2003
Export Citation:
Assignee:
EP-O-PLS GM Behr und Company Carga
International Classes:
A61K38/22; A61K38/18; A61K38/19; A61P9/00; A61P13/12; A61P43/00
Other References:
MONTINI,G. et al,Pharmacokinetics and hematologic response to subcutaneous administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: a multicenter study,J Pediatr,1993年,Vol.122, No.2,p.297-302
MATUSZKIEWICZ-ROWINSKA,J. et al,[Effect of low-dose recombinant humane erythropoietin therapy on the quality of life in patients with anemia in the course of end-stage renal failure treated with dialysis],Pol Arch Med Wewn,1996年,Vol.96, No.2,p.143-52
KRAUSE K,EUROPEAN HEART JOURNAL,2001年 9月,V22 N.ABSTRACT SUPPLEMENT,P154
ARCASOY,M.O. et al,Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing,Blood,2001年,Vol.98, No.11,p.822a-823a
BUEMI M,JOURNAL OF NEPHROLOGY 2002 ITALY,2002年,V15 N2,P97-103
MATUSZKIEWICZ-ROWINSKA,J. et al,[Effect of low-dose recombinant humane erythropoietin therapy on the quality of life in patients with anemia in the course of end-stage renal failure treated with dialysis],Pol Arch Med Wewn,1996年,Vol.96, No.2,p.143-52
KRAUSE K,EUROPEAN HEART JOURNAL,2001年 9月,V22 N.ABSTRACT SUPPLEMENT,P154
ARCASOY,M.O. et al,Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing,Blood,2001年,Vol.98, No.11,p.822a-823a
BUEMI M,JOURNAL OF NEPHROLOGY 2002 ITALY,2002年,V15 N2,P97-103
Attorney, Agent or Firm:
Satoshi Kono
Makoto Nakamura
Kurata Masatoshi
Takashi Mine
Yoshihiro Fukuhara
Toshio Shirane
Sadao Muramatsu
Nobuhisa Nogawa
Katsu Sunagawa
Ryo Hashimoto
Tetsuya Kazama
Makoto Nakamura
Kurata Masatoshi
Takashi Mine
Yoshihiro Fukuhara
Toshio Shirane
Sadao Muramatsu
Nobuhisa Nogawa
Katsu Sunagawa
Ryo Hashimoto
Tetsuya Kazama